Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin + Meropenem vs Ceftazidime for Nosocomial SBP
NCT01455246Phase 3Terminated
- Sponsor
- Università di Padova
- Start
- Oct 2010
- Primary completion
- Apr 2014
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of daptomycin, meropenem in spontaneous bacterial peritonitis (SBP), sponsored by Università di Padova. Started Oct 2010; status: terminated.
02
Drugs
daptomycinmeropenem
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT01455246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455246.